Theoretical and Natural Science · Aug 4, 2026

Artificial Intelligence-Assisted Blood Bi omarker Analysis for Early Detection of Alzheimer's Disease

By Luo Z

Alzheimer's disease (AD) ranks among the most prevalent neurodegenerative diseases globally, and definitive diagnosis is frequently accomplished subsequent to substantial brain damage. Conventional diagnostic methods, including positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) analysis, yield satisfactory diagnostic performance but suffer from high costs and invasiveness. In recent years, blood biomarkers such as amyloid-beta (Aβ), phosphorylated tau (p-tau), and neurofilament light chain (NfL) have emerged as promising tools for earlier and more accessible diagnosis. However, interpreting complex biomarker data remains challenging. Each marker reflect distinct neurodegenerative problem. Artificial intelligence (AI) and machine learning techniques may improve diagnostic accuracy by analyzing multiple biomarkers simultaneously and identifying hidden biological patterns. This paper reviews the role of AI-assisted blood biomarker analysis in the early diagnosis of Alzheimer's disease, discusses major biomarkers currently used in research, summarizes recent findings, and evaluates the opportunities and limitations of AI-based diagnostic approaches. Although several challenges remain, including dataset bias and clinical implementation difficulties, AI-assisted blood testing represents a promising direction for improving large-scale screening and early intervention for Alzheimer's disease. It may also reduce reliance on costly, invasive examinations in healthcare.

doi.org/10.54254/2753-8818/2026.hz35804Open accessBiomarkers

AgingResearch.News